E
Eli Eyal
Publications - 20
Citations - 1457
Eli Eyal is an academic researcher. The author has contributed to research in topics: Rasagiline & Placebo. The author has an hindex of 14, co-authored 19 publications receiving 1312 citations.
Papers
More filters
Journal ArticleDOI
A controlled trial of rasagiline in early Parkinson disease: The tempo study
Andrew Siderowf,Matthew B. Stern,Ira Shoulson,Karl Kieburtz,David Oakes,Denni Day,Aileen Shinaman,Sandra Plumb,Stanley Fahn,Karen Blindauer,Mark F. Lew,Howard I. Hurtig,Mary Lloyd,Robert A. Hauser,Lisa Gauger,Lawrence I. Golbe,Joanne Wojcieszek,Joann Belden,Andrew Feigin,Mary Lou Klimek,Barbara Shannon,William G. Ondo,Christine Hunter,Vincent Calabrese,Paul Atchison,Cathy W. Allen,Frederick J. Marshall,Debra Berry,Irenita Gardiner,Janis M. Miyasaki,Luisa Del Rizzo,Tilak Mendis,Neila Mendis,Peggy Gray,Jean P. Hubble,Karen Betcher,Rajesh Pahwa,Eric Molho,Diane Brown,Lisa M. Shulman,Ali H. Rajput,Marianne Ewanishin,Mark Stacy,Kelli Williamson,John M. Bertoni,Carolyn Peterson,Paul J. Tuite,Brenda Ebbitt,Kathleen M. Shannon,Jean A. Jaglin,Caroline M. Tanner,Kenneth Marek,Karen Stavris,Michael J. Aminoff,Mariann DiMinno,Glenna A. Dowling,Un Jung Kang,Judy Richman,Kapil D. Sethi,W.R. Wayne Martin,Pamela King,Germaine McInnes,Charles H. Adler,Peter A. LeWitt,Maryan DeAngelis,Myrna Schear,Mark Forrest Gordon,Roberta Winnick,Robert G. Feldman,Cathi A. Thomas,Kelly M. Conn,Alicia Brocht,Chris Chadwick,Jeannette Connolly,Susan Daigneault,Shirley Eberly,Janice Bausch,Lee Josephson,Rosemary Oliva,Steven R. Schwid,Anthony E. Lang,Christopher Cox,Carrie Irvine,John G. Nutt,William B. White,Sheila Oren,Ruth Levy,Eli Eyal,David Ladkani,Wayne Houck +89 more
TL;DR: Rasagiline is effective as monotherapy for patients with early PD and the 2 dosages in this trial were both effective relative to placebo.
Journal ArticleDOI
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.
Olivier Rascol,Cheryl Fitzer-Attas,Robert A. Hauser,Joseph Jankovic,Anthony E. Lang,J. William Langston,Eldad Melamed,Werner Poewe,Fabrizio Stocchi,Eduardo Tolosa,Eli Eyal,Yoni M Weiss,C. Warren Olanow +12 more
TL;DR: Findings show that rasagiline delayed the need for symptomatic antiparkinsonian drugs and emphasise the contribution of the UPDRS ADL in the response of the rasgeiline 1 mg per day early-start versus delayed-start groups.
Journal ArticleDOI
A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics
C. Warren Olanow,Robert A. Hauser,Joseph Jankovic,William J. Langston,Anthony E. Lang,Werner Poewe,Eduardo Tolosa,Fabrizio Stocchi,Eldad Melamed,Eli Eyal,Olivier Rascol +10 more
TL;DR: Positive results in a delayed start study indicate that patients who receive early treatment have a better outcome than those where the treatment is delayed, and the rationale for the study and baseline characteristics of the 1,176 patients who have been enrolled into the trial are described.
Journal ArticleDOI
Combined Rasagiline and Antidepressant Use in Parkinson Disease in the ADAGIO Study Effects on Nonmotor Symptoms and Tolerability
TL;DR: A role for dopamine-enhancing therapies in NMSs in early PD is suggested and the combination of rasagiline and antidepressants in patients with de novo PD is associated with reduced worsening of a range of N MSs in preliminary analyses.
Journal ArticleDOI
Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial
Werner Poewe,Klaus Seppi,Cheryl Fitzer-Attas,Gregor K. Wenning,Sid Gilman,Phillip A. Low,Nir Giladi,Paolo Barone,Cristina Sampaio,Eli Eyal,Olivier Rascol +10 more
TL;DR: Treatment with rasagiline 1 mg per day did not show a significant benefit as assessed by UMSARS, and the study confirms the sensitivity of clinical outcomes for multiple system atrophy to detect clinically significant decline, even in individuals with early disease.